CLC bio is the latest company to participate in the European FP7 project, STATegra. It will receive $1.3 million out of the total $7.8 million budget for its efforts. The STATegra project aims to develop an integral analysis platform for different omics data that is capable of providing a more efficient use of genomics technologies. This project will generate and integrate data obtained in proteomic, metabolomics, and epigenomic experiments.
"One of the big challenges today is going past the raw sequence data and getting to grips with the complexity of epigenetic processes - how, when, and why are certain genes switched off or expressed?" states Dr. Michael Lappe, Ph.D., senior bioinformatics scientist at CLC bio. "We aim to leverage a framework which makes this extremely complex network biology understandable. Ultimately our tools will facilitate the translation of massive amounts of data into useful insights that can be applied in clinical settings."
Within the overall project, methods for the validation and design of follow-up studies are implemented. Utilizing and validating existing datasets, STATegra is also going to feed its experimental results back into the public domain.
Additional partners on the project are Biomax Informatics, Karolinska Institutet, Imperial College of Science, Technology and Medicine, Foundation for Research and Technology-Hellas, Institut d’Investigació Biomèdica de Bellvitge, University of Amsterdam, University of Leiden, the Ludwig-Maximilians University of Munich, University of California. The project is coordinated by Dr. Ana Conesa from the Computational Medicine Institute of the Prince Felipe Research Centre.